ACADIA PHARMACEUTICALS INC. Net Income (Loss) Available to Common Stockholders, Diluted
ACADIA PHARMACEUTICALS INC. (ACAD) reported Net Income (Loss) Available to Common Stockholders, Diluted of $31.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $31.50M, a 18.13% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $3.64M, a 80.84% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $273.57M, a 90.32% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $71.78M, a 119.07% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $391.00M, a 72.66% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was $226.45M.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$61.29M.
- ACADIA PHARMACEUTICALS INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$215.97M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.50M 10-Q · filed 2026-08-05 | $35.14M 10-Q · filed 2026-08-05 | $308.70M derived: sum of 3 quarters · filed 2026-08-05 | $380.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.64M 10-Q · filed 2026-05-07 | $277.20M derived: sum of 2 quarters · filed 2026-05-07 | $348.98M derived: sum of 3 quarters · filed 2026-05-07 | $375.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $273.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $345.35M derived: sum of 2 quarters · filed 2026-02-26 | $372.01M derived: sum of 3 quarters · filed 2026-08-05 | $391.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $71.78M 10-Q · filed 2025-11-06 | $98.44M derived: sum of 2 quarters · filed 2026-08-05 | $117.43M 10-Q · filed 2025-11-06 | $261.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $26.67M 10-Q · filed 2026-08-05 | $45.65M 10-Q · filed 2026-08-05 | $189.40M derived: sum of 3 quarters · filed 2026-08-05 | $222.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $18.99M 10-Q · filed 2026-05-07 | $162.73M derived: sum of 2 quarters · filed 2026-05-07 | $195.49M derived: sum of 3 quarters · filed 2026-05-07 | $228.88M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $143.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $176.51M derived: sum of 2 quarters · filed 2026-02-26 | $209.90M derived: sum of 3 quarters · filed 2026-02-26 | $226.45M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.77M 10-Q · filed 2025-11-06 | $66.15M derived: sum of 2 quarters · filed 2025-11-06 | $82.71M 10-Q · filed 2025-11-06 | $128.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $33.39M 10-Q · filed 2025-08-07 | $49.94M 10-Q · filed 2025-08-07 | $95.74M derived: sum of 3 quarters · filed 2026-02-26 | $30.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $16.55M 10-Q · filed 2025-05-08 | $62.35M derived: sum of 2 quarters · filed 2026-02-26 | -$2.82M derived: sum of 3 quarters · filed 2026-02-26 | -$1.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $45.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$19.38M derived: sum of 2 quarters · filed 2026-02-26 | -$18.27M derived: sum of 3 quarters · filed 2026-02-26 | -$61.29M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$65.18M 10-Q · filed 2024-11-07 | -$64.06M derived: sum of 2 quarters · filed 2024-11-07 | -$107.08M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.11M 10-Q · filed 2024-08-07 | -$41.91M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$43.02M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$215.97M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |